EyeGene Inc. (KOSDAQ: A185490)
Health Care · Biotechnology · KR
₩1,951.00
+4.33% today · -14.1% 1Y
EyeGene Inc. (KOSDAQ: A185490) operates in the Biotechnology industry within the Health Care sector. The company is valued at $63.26M.
Over the last twelve months the share price has lost 14.1%, trading between 1.18K and 2.81K.
Tweenvest scores EyeGene Inc. across four factors: quality 49/100, value 65/100. Its strongest factor is value.
A185490 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $63.26M
- Revenue (TTM)
- $2.89M
- P/E
- —
- EPS
- -486.92
- Dividend yield
- —
- Beta (5Y)
- 0.71
- 52-week high
- ₩2,805.00
- 52-week low
- ₩1,182.00
- Avg volume (3M)
- —
- Shares outstanding
- 43.23M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| XBiotech Inc.NasdaqGS: XBIT | $64.63M | $2.12 | -7.42% |
| iNtRON Biotechnology, Inc.KOSDAQ: A048530 | $64.53M | ₩2,785.00 | -2.11% |
| Fortress Biotech, Inc.NasdaqCM: FBIO | $64.37M | $1.93 | -3.02% |
| Oncolytics Biotech Inc.NasdaqCM: ONCY | $63.51M | $0.50 | -10.57% |
| Nuo Therapeutics, Inc.OTCPK: AURX | $62.96M | $1.30 | +4.00% |
| OS Therapies IncorporatedNYSEAM: OSTX | $60.89M | $1.32 | -18.52% |
| Pharos iBio Co., Ltd.KOSDAQ: A388870 | $60.30M | ₩6,210.00 | -3.12% |
| Hemogenyx Pharmaceuticals PlcLSE: HEMO | $59.69M | £6.58 | -10.48% |
Figures last refreshed Oct 18, 2026.